A Phase 1 interventional study of TAK-935 and [18F]MNI-792 (tracer) in Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 793 studies in Epilepsy with a site in United States — 161 open to participants now, 194 under way, 17 of them phase 3. Epilepsy · United States.
Among the 793 studies in Epilepsy with a site in United States, this one is the 470th largest by enrollment of the 588 interventional ones that give a count, is one of 38 that started in 2015, is one of 66 in phase 1, and was the 382nd registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →161 of the 793 studies in Epilepsy with a site in United States are open now. Recruiting first, the newest first:
Cadence Neuroscience · Sites in United States
Ages 7+ · Men only
Duke University · Sites in United States
Ages 18–70
NeuroOne Medical Technologies Corporation · Sites in United States
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of
Ages 18–75
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 13–29
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 19 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
793 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 82 · Phase 2 126 · Phase 3 133 · Phase 4 51
First in 1975; this study’s year is marked. 38 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 40 across the 588 interventional studies, 90 across the 193 observational. Of the 526 that completed or were terminated, 243 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
295 of 793 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 5 studies filed under Epilepsy — fewer than ten, so there is no comparison to draw.
72 of the studies in Epilepsy with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT07010471Phase 3Praxis Precision MedicinesA Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine | 2026-12 |
| NCT07019922Phase 3Praxis Precision MedicinesA Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | 2026-12 |
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT05431595Phase 3M.D. Anderson Cancer CenterManaging Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy | 2027-02-02 |
Add all 72 to your calendar (.ics) → With an account.
Among the 793 studies in Epilepsy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the brain cholesterol 24S-hydroxylase (CH24H) enzyme occupancy of TAK-935 after single oral dose in healthy participants using the positron emission tomography (PET) ligand [18F]MNI-792 and PET imaging and to determine the relationship of occupancy to TAK-935 exposure.
The drug being tested in this study is called TAK-935. TAK-935 is being tested to examine the degree and duration of brain CH24H enzyme occupancy/target engagement as a function of TAK-935 plasma concentration in order to guide dosing and schedule for future clinical trials with TAK-935. This study will utilize the PET ligand [18F]MNI-792 to evaluate the brain CH24H occupancy of TAK-935 after single dose oral administration in healthy adult participants. The study will evaluate up to 16 participants. The first 2 participants will take TAK-935 600 mg oral solution and undergo PET imaging using tracer [18F]MNI-792 up to 5 mcg (up to 370 MBq), injection, intravenously prior to each PET scan at Baseline, 45 minutes and 10 hours post-TAK-935 dose. TAK-935 dose and timing of post-dose scans for subsequent participants will be based on the data from the previous participants. This single-center trial will be conducted in the United States. The overall time to participate in this study is up to 55 days. Participants will make 4 visits to the clinic, including 2 confinement periods to the clinic for PET imaging. Participants will be contacted by phone on Day 28 for follow-up safety assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of TAK-935 600 milligram (mg), oral solution on Day 1 as a starting dose and up to 370 megabecquerel (MBq) (10 millicurie \[mCi\]) of \[18F\]MNI-792 with a mass of up to 5 microgram (mcg), injection intravenously (IV), prior to each PET imaging at Baseline, 45 minutes and 10 hours post-TAK-935 dose. Subsequent dose of TAK-935 oral solution and timing of PET imaging will be based on safety, tolerability and occupancy data from previous level participants.
Drug: TAK-935 · Drug: [18F]MNI-792 (tracer)
TAK-935 oral solution.
\[18F\]MNI-792 injection.
Cholesterol 24S-Hydroxylase (CH24H) Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 45 Minutes Post-TAK-935 Dose
CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: total volume of distribution \[VT\] (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - non-displaceable volume of distribution \[VND\]), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept. Data was reported only for TAK-935 600 mg because only first two participants were analyzed at 45 minutes post-TAK-935 dose.
Time frame: 45 minutes post-TAK-935 dose
CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose
CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept.
Time frame: 2 hours post-TAK-935 dose
CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 10 Hours Post-TAK-935 Dose
CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept. Data was reported only for TAK-935 600 mg because only first two participants were analyzed at 10 hour post-TAK-935 dose.
Time frame: 10 hours post-TAK-935 dose
CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose
CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept.
Time frame: 24 hours post-TAK-935 dose
Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods
Time frame: At time 0 (just after tracer injection), 1 hour after tracer injection and 2 hours after tracer injection for each post-TAK-935 dosing PET scan period
Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC)
Percent change was calculated as = \[(Postdose AUEC24(2) - Baseline AUEC24(2))/Baseline AUEC24(2)\]\*100 percent.
Time frame: Baseline (Day -1): 1 hour and at multiple timepoints (up to 12 hours) post check in and Day 1: pre-dose and at multiple timepoints (up to 24 hours) post-TAK-935 dose
Participants took part in the study at 1 investigative site in the United States from 01 July 2015 to 04 January 2016.
| Milestone | TAK-935 50 mg | TAK-935 100 mg | TAK-935 200 mg | TAK-935 300 mg | TAK-935 600 mg |
|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 3 |
| Completed | 2 | 2 | 2 | 2 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: total volume of distribution \[VT\] (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - non-displaceable volume of distribution \[VND\]), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept. Data was reported only for TAK-935 600 mg because only first two participants were analyzed at 45 minutes post-TAK-935 dose.
| percentage of occupancy | TAK-935 600 mg |
|---|---|
| Participant 1 | NA |
| Participant 2 | 98 |
| Participant 3 | NA |
CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept.
| percentage of occupancy | TAK-935 50 mg | TAK-935 100 mg | TAK-935 200 mg | TAK-935 300 mg | TAK-935 600 mg |
|---|---|---|---|---|---|
| Participant 1 | 70 | 79 | 96 | 91 | NA |
| Participant 2 | 64 | 85 | 89 | 89 | NA |
| Participant 3 | NA | NA | NA | NA | 96 |
CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept. Data was reported only for TAK-935 600 mg because only first two participants were analyzed at 10 hour post-TAK-935 dose.
| percentage of occupancy | TAK-935 600 mg |
|---|---|
| Participant 1 | 92 |
| Participant 2 | 87 |
| Participant 3 | NA |
CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept.
| percentage of occupancy | TAK-935 50 mg | TAK-935 100 mg | TAK-935 200 mg | TAK-935 300 mg | TAK-935 600 mg |
|---|---|---|---|---|---|
| Participant 1 | 22 | 13 | 79 | 46 | NA |
| Participant 2 | 11 | NA | 47 | 27 | NA |
| Participant 3 | NA | NA | NA | NA | 52 |
| nanogram per milliliter (ng/mL) | TAK-935 50 mg | TAK-935 100 mg | TAK-935 200 mg | TAK-935 300 mg | TAK-935 600 mg |
|---|---|---|---|---|---|
| Participant 1: PET Scan 1: pre-tracer dose | 9.16 | 11.3 | 158 | 56.2 | 6.83 |
| Participant 1: PET Scan 1: 1 hour post-tracer dose | 3.79 | 5.02 | 72.7 | 19.4 | 200 |
| Participant 1:PET Scan 1: 2 hours post-tracer dose | 2.98 | 2.45 | 30.3 | 12.9 | 379 |
| Participant 1: PET Scan 2: pre-tracer dose | NA | NA | 14.2 | NA | 22.3 |
| Participant 1:PET Scan 2: 1 hour post-tracer dose | NA | NA | 9.16 | NA | 16 |
| Participant 1:PET Scan 2:2 hours post-tracer dose | NA | NA | 8.08 | NA | 14.4 |
| Participant 2: PET Scan 1: pre-tracer dose | 6.92 | 23.9 | 34.8 | 50.9 | 569 |
| Participant 2: PET Scan 1: 1 hour post-tracer dose | 2.97 | 12.3 | 16.8 | 15.7 | 257 |
| Participant 2:PET Scan 1: 2 hours post-tracer dose | 1.95 | 6.46 | 7.52 | 14.6 | 90.8 |
| Participant 2: PET Scan 2: pre-tracer dose | NA | 1.83 | NA | NA | 7.99 |
| Participant 2:PET Scan 2: 1 hour post-tracer dose | NA | 1.28 | NA | NA | 6.27 |
| Participant 2:PET Scan 2:2 hours post-tracer dose | NA | NA | NA | NA | 5.12 |
| Participant 3: PET Scan 1: pre-tracer dose | NA | NA | NA | NA | 589 |
| Participant 3: PET Scan 1: 1 hour post-tracer dose | NA | NA | NA | NA | 236 |
| Participant 3:PET Scan 1: 2 hours post-tracer dose | NA | NA | NA | NA | 155 |
| Participant 3: PET Scan 2: pre-tracer dose | NA | NA | NA | NA | 3.04 |
| Participant 3: PET Scan 2: 1 hour post-tracer dose | NA | NA | NA | NA | 2.58 |
| Participant 3:PET Scan 2: 2 hours post-tracer dose | NA | NA | NA | NA | 2.24 |
Percent change was calculated as = \[(Postdose AUEC24(2) - Baseline AUEC24(2))/Baseline AUEC24(2)\]\*100 percent.
| percent change | TAK-935 50 mg | TAK-935 100 mg | TAK-935 200 mg | TAK-935 300 mg | TAK-935 600 mg |
|---|---|---|---|---|---|
| Participant 1 | -6.79 | -14.82 | -10.50 | -12.41 | -7.23 |
| Participant 2 | -13.38 | -15.04 | -9.30 | -18.55 | -12.79 |
| Participant 3 | NA | NA | NA | NA | -6.81 |
Collected over Baseline up to Day 28. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baseline [18F]MNI-792 | — | 0/11 (0%) | 1/11 (9.1%) |
| TAK-935 50 mg | — | 0/2 (0%) | 1/2 (50%) |
| TAK-935 100 mg | — | 0/2 (0%) | 1/2 (50%) |
| TAK-935 200 mg | — | 0/2 (0%) | 1/2 (50%) |
| TAK-935 300 mg | — | 0/2 (0%) | 1/2 (50%) |
| TAK-935 600 mg | — | 0/3 (0%) | 1/3 (33.3%) |
| Event | Baseline [18F]MNI-792 | TAK-935 50 mg | TAK-935 100 mg | TAK-935 200 mg | TAK-935 300 mg | TAK-935 600 mg |
|---|---|---|---|---|---|---|
| TinnitusEar and labyrinth disorders | 0/11 | 1/2 | 0/2 | 0/2 | 0/2 | 0/3 |
| Catheter site haemorrhageGeneral disorders | 0/11 | 0/2 | 0/2 | 1/2 | 0/2 | 0/3 |
| PresyncopeNervous system disorders | 0/1 | 0/2 | 1/2 | 0/2 | 0/2 | 0/3 |
| HypertensionVascular disorders | 0/11 | 0/2 | 0/2 | 0/2 | 1/2 | 0/3 |
| Blood creatine phosphokinase increasedInvestigations | 0/11 | 0/2 | 0/2 | 0/2 | 0/2 | 1/3 |
| SyncopeNervous system disorders | 1/11 | 0/2 | 0/2 | 0/2 | 0/2 | 0/3 |
Safety analysis set included all participants who were enrolled and received investigational drug (\[18F\]MNI-792 or TAK-935).
| Age, Continuous(years) | TAK-935 50 mg | TAK-935 100 mg | TAK-935 200 mg | TAK-935 300 mg | TAK-935 600 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 40.0 ± 7.07 | 25.5 ± 2.12 | 42.0 ± 2.83 | 48.5 ± 2.12 | 36.7 ± 6.11 | 38.4 ± 8.48 |
| Sex/Gender, Customized(participants) | TAK-935 50 mg | TAK-935 100 mg | TAK-935 200 mg | TAK-935 300 mg | TAK-935 600 mg | Total |
|---|---|---|---|---|---|---|
| Male | 2 | 2 | 2 | 2 | 3 | 11 |
| Region of Enrollment(participants) | TAK-935 50 mg | TAK-935 100 mg | TAK-935 200 mg | TAK-935 300 mg | TAK-935 600 mg | Total |
|---|---|---|---|---|---|---|
| United States | 2 | 2 | 2 | 2 | 3 | 11 |
| Ethnicity(participants) | TAK-935 50 mg | TAK-935 100 mg | TAK-935 200 mg | TAK-935 300 mg | TAK-935 600 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 0 | 0 | 1 | 4 |
| Not Hispanic or Latino | 1 | 0 | 2 | 2 | 2 | 7 |
| Race(participants) | TAK-935 50 mg | TAK-935 100 mg | TAK-935 200 mg | TAK-935 300 mg | TAK-935 600 mg | Total |
|---|---|---|---|---|---|---|
| Black or African American | 2 | 1 | 2 | 0 | 1 | 6 |
| White | 0 | 1 | 0 | 2 | 2 | 5 |
| Height(centimeter (cm)) | TAK-935 50 mg | TAK-935 100 mg | TAK-935 200 mg | TAK-935 300 mg | TAK-935 600 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 171.5 ± 4.95 | 181.5 ± 3.54 | 177.0 ± 4.24 | 180.0 ± 0.00 | 183.0 ± 16.09 | 179.0 ± 8.69 |
| Weight(kilogram (kg)) | TAK-935 50 mg | TAK-935 100 mg | TAK-935 200 mg | TAK-935 300 mg | TAK-935 600 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 86.05 ± 7.283 | 93.60 ± 10.748 | 79.40 ± 12.869 | 87.05 ± 5.162 | 84.83 ± 23.692 | 86.06 ± 13.009 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | TAK-935 50 mg | TAK-935 100 mg | TAK-935 200 mg | TAK-935 300 mg | TAK-935 600 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 29.22 ± 0.789 | 28.37 ± 2.157 | 25.46 ± 5.327 | 26.87 ± 1.593 | 24.95 ± 4.275 | 26.79 ± 3.212 |
The record gives a start of Jul 2015, a primary completion of Dec 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Soticlestat · Spinosad